An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells

Reddy, Neetinkumar D.; Shoja, Muhammed Haneefa; Biswas, Subhankar; Nayak, Pawan G.; Kumar, Nitesh; Rao, C. Mallikarjuna

doi:10.1016/j.cbi.2016.05.008

Cited by 34 publications

(21 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown that the chemical components of cinnamon exert anti-tumor effects. Cinnamic acid derivatives can inhibit the growth of lung cancer cells (A549), breast cancer cells (MCF-7), and MCF-10A (Reddy et al, 2016). Cinnamon essential oil is cytotoxic in vitro and exhibits certain inhibitory effects on PC3, A549, and MCF-7 prostate cancer cells, with PC3 exerting the strongest inhibitory effect (Zu et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

Targets and Mechanism Used by Cinnamaldehyde, the Main Active Ingredient in Cinnamon, in the Treatment of Breast Cancer

Liu

Wan

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Breast cancer has become one of the most common malignant tumors in women owing to its increasing incidence each year. Clinical studies have shown that Cinnamomum cassia (L.) J. Presl (cinnamon) has a positive influence on the prevention and treatment of breast cancer.Aim: We aimed to screen the potential targets of cinnamon in the treatment of breast cancer through network pharmacology and explore its potential therapeutic mechanism through cell experiments.Methods: We used the TCMSP, TCM Database @ Taiwan, and TCMID websites and established the active ingredient and target database of cinnamon. Thereafter, we used the GeneCards and OMIM databases to establish a breast cancer-related target database, which matched the cinnamon target database. Based on the matching results, the STRING database was used to analyze the interaction between the targets, and the biological information annotation database was used to analyze the biological process of the target (gene ontology) and the pathway enrichment of Kyoto Encyclopedia of Genes and Genomes (KEGG). After establishing the layout of the analysis, we used Cytoscape 3.6.0 software for network analysis. Finally, the cell experiment was used to verify the anti-breast cancer effect of cinnamaldehyde.Results: Our research showed that the main components of cinnamon, including cinnamaldehyde, can play a role in the treatment of breast cancer through 59 possible important targets. Subsequently, enrichment analysis by gene ontology and Kyoto Encyclopedia of Genes and Genomes showed that 83 cell biological processes and 37 pathways were associated with breast cancer (p < 0.05), including the peroxisome proliferator-activated receptor and PI3K-Akt pathway, which are closely related to tumor cell apoptosis. In vitro cell verification experiments showed that cinnamaldehyde can significantly inhibit cell proliferation, change cell morphology, inhibit cell migration and invasion ability, and promote cell apoptosis.Conclusion: Our results showed that cinnamaldehyde is a potential novel drug for the treatment and prevention of breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Targets and Mechanism Used by Cinnamaldehyde, the Main Active Ingredient in Cinnamon, in the Treatment of Breast Cancer

Liu

Wan

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…23) In the current study, exposure of T24R2 cells to cisplatin and SAHA (pan HDAC inhibitor) treatment resulted in cell cycle arrest at the subG1 phase and S phase, although an valproic acid (HDAC inhibitor type I, IIa) induced G1 phase cell cycle arrest in time-and dose-dependent manners in muscle-invasive human bladder cancer cell lines. 24) Cyclins A, D1, and E are known as G1/S-phase regulators 25,26) while p21 is also a crucial regulator of cell cycle progression in the G1 and S phases and a directly inhibit DNA synthesis by binding to proliferating cell nuclear antigen (PCNA). 23,27) The present study revealed combination treatment with SAHA and cisplatin significantly reduced the expressions of S phaserelated proteins including cyclins A2, D1, and E1, resulting in S phase cell cycle arrest.…”

Section: Discussionmentioning

confidence: 99%

Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer

Ryu

Jin

et al. 2019

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Cisplatin chemotherapy is the standard treatment for metastatic urothelial carcinoma. Although there are second-line chemotherapeutic agents approved by the U.S. Food and Drug Administration (FDA) such as those targeting programmed death-ligand 1 (PD-L1), more effective pharmacotherapy is required for cisplatin-resistant bladder cancer due to its limited overall survival and progression-free survival. The synergistic anti-cancer effect of cisplatin and suberoylanilide hydroxamic acid (SAHA) in cisplatin-resistant bladder cancer cells (T24R2) was examined. Tumor cell proliferation and cell cycle was examined using the cell counting kit (CCK)-8 assays and flow cytometry, respectively. Synergism was examined using the combination index (CI). CCK-8 assay and CI test were used to observe the strong synergistic anti-cancer effect between SAHA and cisplatin. Activation of caspase mediated apoptosis, down-regulated expression of the anti-apoptotic B-cell lymphoma-2 (Bcl-2) and up-regulated expression of pro-apoptotic Bcl-2-associated death promoter (BAD) were observed in Western blot. SAHA synergistically could partially re-sensitize cisplatin-resistant bladder cancer cells (T24R2) through the cell cycle arrest and induction of apoptosis pathway. SAHA-based treatment could be a potential treatment regimen in patients with cisplatin resistant bladder cancer.

show abstract

“…In around half of all cancers, p53 is thought to be inactive. A number of anticancer mechanisms are activated by p53 (Figure 4) [32][33][34][35].…”

Section: Tumor Suppression Marker P53mentioning

confidence: 99%

Biochemical and Molecular Diagnostic Indicators for Cancer

Baskaran¹,

Vignesh²,

Chandrasekar³

2021

COR

View full text Add to dashboard Cite

Biomarkers are substances that are either secreted by the tumor or produced by the body in response to the presence of cancer. Biomarkers serve as an objective measure for evaluation of normal and pathological processes as well as pharmacological responses to a therapeutic intervention. Cancer studies are usually difficult to interpret, especially based on the contemporary medical diagnosis. In this circumstance, biomarkers are developing as reliable diagnostic metabolites, which have many promising applications in oncological screening, differential diagnosis, risk assessment, response to treatment, and examining the progression of disease. Genome or protein based prognostic biomarkers are available, for numerous cancer types, for potential inclusion into clinical prognostic staging methods. However, there lies difficulty in translating these biomarkers into clinical outcomes. This review concerns important biomarkers related to wide varieties of cancer and also elucidates mode of action of few major biomarkers.

show abstract

An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells

Cited by 34 publications

References 49 publications

Targets and Mechanism Used by Cinnamaldehyde, the Main Active Ingredient in Cinnamon, in the Treatment of Breast Cancer

Targets and Mechanism Used by Cinnamaldehyde, the Main Active Ingredient in Cinnamon, in the Treatment of Breast Cancer

Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer

Biochemical and Molecular Diagnostic Indicators for Cancer

Contact Info

Product

Resources

About